Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co?

Bristol-Myers Squibb  (NYSE: BMY) has one of the largest dividends in health care, but does that make it one of the sector's top dividend stocks? 

In this video, Motley Fool Healthcare analyst David Williamson will be grading well known dividend stocks using a World Cup inspired grading system: a yellow card is a warning for investors, a red card is an ejection, and a "goal" happens if the stock looks like a winner. 

Watch and find out the current strengths and weaknesses of Bristol and if it should be ejected by investors.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

 

The article Should Dividend Investors Keep or Eject Bristol-Myers Squibb Co? originally appeared on Fool.com.

David Williamson owns shares of Merck. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

Small Cap Investing

Learn now to invest in small companies the right way.

View Course »

Behavioral Finance

Why do investors make the decisions that they do?

View Course »

Add a Comment

*0 / 3000 Character Maximum